Meta-analysis: Anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients

被引:423
作者
Dentali, Francesco
Douketis, James D.
Gianni, Monica
Lim, Wendy
Crowther, Mark A.
机构
[1] McMaster Univ, Hamilton, ON, Canada
[2] St Josephs Healthcare Hamilton, Hamilton, ON, Canada
关键词
D O I
10.7326/0003-4819-146-4-200702200-00007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Underutilization of anticoagulant prophylaxis may be due to lack of evidence that prophylaxis prevents clinically important outcomes in hospitalized medical patients at risk for venous thromboembolism. Purpose: To assess the effects of anticoagulant prophylaxis in reducing clinically important outcomes in hospitalized medical patients. Data Sources: MEDLINE, EMBASE, and Cochrane databases were searched to September 2006 without language restrictions. Study selection: Randomized trials comparing anticoagulant prophylaxis with no treatment in hospitalized medical patients. Data Extraction: Any symptomatic pulmonary embolism (PE), fatal PE, symptomatic deep venous thrombosis, all-cause mortality, and major bleeding. Pooled relative risks and associated 95% Cls were calculated. For treatment effects that were statistically significant, the authors determined the absolute risk reduction and the number needed to treat for benefit (NNTB) to prevent an outcome. Data Synthesis: 9 studies (n = 19 958) were included. During anticoagulant prophylaxis, patients had significant reductions in any PE (relative risk, 0.43 [Cl, 0.26 to 0.71]; absolute risk reduction, 0.29%; NNTB, 345) and fatal PE (relative risk, 0.38 [Cl, 0.21 to 0.69]; absolute risk reduction, 0.25%; NNTB, 400), a nonsignificant reduction in symptomatic deep venous thrombosis (relative risk, 0.47 [Cl, 0.22 to 1.00]), and a nonsignificant increase in major bleeding (relative risk, 1.32 [Cl, 0.73 to 2.37]). Anticoagulant prophylaxis had no effect on all-cause mortality (relative risk, 0.97 [Cl, 0.79 to 1.19]). Limitations: 2 of 9 included studies were not double-blind. Conclusions: Anticoagulant prophylaxis is effective in preventing symptomatic venous thromboembolism during anticoagulant prophylaxis in at-risk hospitalized medical patients. Additional research is needed to determine the risk for venous thromboembolism in these patients after prophylaxis has been stopped.
引用
收藏
页码:278 / 288
页数:11
相关论文
共 51 条
[1]   Risk factors for venous thromboembolism in hospitalized patients with acute medical illness - Analysis of the MEDENOX study [J].
Alikhan, R ;
Cohen, AT ;
Combe, S ;
Samama, MM ;
Desjardins, L ;
Eldor, A ;
Janbon, C ;
Leizorovicz, A ;
Olsson, CG ;
Turpie, AGG .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (09) :963-968
[2]  
ALLEN TW, 1996, J AM OSTEOPATH ASSOC, V96, P335
[3]   PREVENTION OF DEEP-VEIN THROMBOSIS IN MEDICAL PATIENTS BY LOW-DOSE HEPARIN [J].
BELCH, JJ ;
LOWE, GDO ;
WARD, AG ;
FORBES, CD ;
PRENTICE, CRM .
SCOTTISH MEDICAL JOURNAL, 1981, 26 (02) :115-117
[4]   Heparin prophylaxis in bedridden patients [J].
Bergmann, JF ;
Caulin, C .
LANCET, 1996, 348 (9021) :205-206
[5]  
Bergmann JF, 1996, THROMB HAEMOSTASIS, V76, P529
[6]   HIGH-RISK OF THE CRITICALLY ILL FOR VENOUS THROMBOEMBOLISM [J].
CADE, JF .
CRITICAL CARE MEDICINE, 1982, 10 (07) :448-450
[7]  
Caprini JA, 2002, INT ANGIOL, V21, P78
[8]   Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial [J].
Cohen, AT ;
Davidson, BL ;
Gallus, AS ;
Lassen, MR ;
Prins, MH ;
Tomkowski, W ;
Turpie, AGG ;
Egberts, JFM ;
Lensing, AWA .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7537) :325-327
[9]   REDUCTION IN FATAL PULMONARY-EMBOLISM AND VENOUS THROMBOSIS BY PERIOPERATIVE ADMINISTRATION OF SUBCUTANEOUS HEPARIN - OVERVIEW OF RESULTS OF RANDOMIZED TRIALS IN GENERAL, ORTHOPEDIC, AND UROLOGIC SURGERY [J].
COLLINS, R ;
SCRIMGEOUR, A ;
YUSUF, S ;
PETO, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (18) :1162-1173
[10]  
DAHAN R, 1986, HAEMOSTASIS, V16, P159